ISOFOL Stock Overview
A clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Isofol Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.28 |
| 52 Week High | SEK 4.89 |
| 52 Week Low | SEK 0.45 |
| Beta | 1.89 |
| 11 Month Change | -17.09% |
| 3 Month Change | 22.20% |
| 1 Year Change | 316.67% |
| 33 Year Change | -66.20% |
| 5 Year Change | -84.33% |
| Change since IPO | -87.87% |
Recent News & Updates
Recent updates
We're Interested To See How Isofol Medical (STO:ISOFOL) Uses Its Cash Hoard To Grow
Jul 12
An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued
May 18Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation
Nov 09Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?
May 12Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)
Apr 08Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment
Mar 03We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully
Jan 10
Shareholder Returns
| ISOFOL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 8.8% | -5.6% | -3.6% |
| 1Y | 316.7% | 17.3% | 12.3% |
Return vs Industry: ISOFOL exceeded the Swedish Biotechs industry which returned 17.3% over the past year.
Return vs Market: ISOFOL exceeded the Swedish Market which returned 12.3% over the past year.
Price Volatility
| ISOFOL volatility | |
|---|---|
| ISOFOL Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ISOFOL's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ISOFOL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 4 | Petter Lindqvist | isofolmedical.com |
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.
Isofol Medical AB (publ) Fundamentals Summary
| ISOFOL fundamental statistics | |
|---|---|
| Market cap | SEK 528.96m |
| Earnings (TTM) | -SEK 39.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.5x
P/E RatioIs ISOFOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISOFOL income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 37.30m |
| Gross Profit | -SEK 37.29m |
| Other Expenses | SEK 1.98m |
| Earnings | -SEK 39.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ISOFOL perform over the long term?
See historical performance and comparison